Document text
Principal Investigator: JOHN P COOKE
Organization: ALBERT EINSTEIN COLLEGE OF MEDICINE
Fiscal Year: 2024
Award: $333,348
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY
RNA vaccines have quicker development timelines and are simpler to manufacture than traditional vaccines.
Combining this strength of RNA technology with protein engineering, they hold the potential to generate highly
efficacious vaccines rapidly that can target and harness the immune system to counter their target virus. Further,
since they can be rapidly synthesized, modifications can be made to maintain efficacy even when the target virus
may undergo mutation in the population. Finally, as RNA vaccines are transient in the vaccinee, do not
incorporate into the genome or require nuclear delivery, and do not encode an entire pathogen, they have a
lower risk profile than other genetic immunization strategies. Therefore, a major component of this application is
to generate efficacious RNA vaccine candidates. To accomplish this development (Aim1), our core will support
Projects 1-3 by generating RNA for their potential engineering and screening. Once a lead antigen is selected,
we will generate both mRNA and self-amplifying replicon mRNA (repRNA) encoding the same antigens to
compare the safety and effectiveness of the immune response to the two different RNA vaccine platforms. To
continue to innovate (Aim 2) and improve our mRNA and repRNA platforms to reduce reactogenicity, increase
stability, and enhance translational efficiency of the RNA constructs, we will prepare antigen gene sequences
with alternative, artificial intelligence-guided codon usage, and incorporate novel lipids into our lipid
nanoparticles. Finally, we can assist our colleagues to make the transition from research to GLP studies by
generating clinical grade RNA constructs in support of rigorous pre-clinical studies.
Terms: <2019-nCoV vaccine><AI system><Antigens><Artificial Intelligence><Assay><Bioassay><Biological Assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 years><Cell Body><Cells><Client><Clinic><Clinical><Codon><Codon Nucleotides><Collaborations><Computer Reasoning><Cyclic GMP><Development><Development and Research><Discipline><Drug Design><Effectiveness><Emergencies><Emergency Situation><Encapsulated><Engineering><Ensure><Freeze Drying><Freeze Dryings><Gene Expression><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genome><Goals><Guanosine Cyclic Monophosphate><Hospitals><Immune response><Immune system><Immunological response><Immunotherapeutic agent><Lead><Leadership><Lipids><Lyophilization><Machine Intelligence><Messenger RNA><Methodist Church><Methodists><Modification><Molecular><Mutation><Non-Polyadenylated RNA><Nuclear><Nucleosides><Other Genetics><Pb element><Population><Position><Positioning Attribute><Preclinical Testing><Procedures><Process><Production><Proliferating><Protein Engineering><R & D><R&D><R-Series Research Projects><R01 Mechanism><R01 Program><RNA><RNA Gene Products><RNA based therapeutics><RNA based therapy><RNA therapy><RNA vaccine><RNA-based vaccine><Replication Unit><Replicon><Research><Research Grants><Research Project Grants><Research Projects><Ribonucleic Acid><Risk><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><Safety><Scientist><Services><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Specificity><Structure><Technology><Therapeutic><Vaccinee><Vaccines><Validation><Virus><Work><cGMP><clinical translation><clinically translatable><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><design><design and construct><design and construction><designing><developmental><experience><genetic immunization><genetic immunization strategies><genetic protein engineering><genome mutation><heavy metal Pb><heavy metal lead><host response><immune drugs><immune system response><immune-based therapeutics><immunogen><immunogenicity><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><improved><in vivo><innovate><innovation><innovative><insight><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><manufacture><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><novel><pathogen><pre-clinical study><pre-clinical testing><preclinical study><protein design><research and development><screening><screenings><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><therapeutic RNA><timeline><tool development><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine platform><vaccine strategy><vaccines preventing COVID><vaccines to prevent COVID><validations><virology>